RecruitingNCT05728957

Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors

Sponsor

Loyola University

Enrollment

100 participants

Start Date

Feb 1, 2023

Study Type

OBSERVATIONAL

Conditions

Kidney Tumor Renal Malignant Tumor Renal Benign Neoplasm

Summary

The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors. To estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC. Participants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating several tools — kidney biopsy, a specialized type of kidney evaluation called PEER, and a nuclear imaging scan (99mTc-sestamibi SPECT/CT) — to better characterize small kidney tumors and determine if they are cancerous before deciding on treatment. **You may be eligible if...** - You have been diagnosed with a small kidney tumor (7 cm or less, clinical stage T1) that appears suspicious on imaging - You are over 18 years old - You have recent CT scans of the mass with and without contrast **You may NOT be eligible if...** - Your tumor has already been confirmed as cancer by prior biopsy - Your kidney function is too low for safe biopsy - You are unable to undergo the required imaging procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.